Who are the tubeworms' relatives?
Vestimentiferan tubeworms belong to the small polychaete family Siboglinidae (Figure 1 ). Unlike other polychaetes, siboglinids share an obligate symbiotic life style in chemosynthesis-based ecosystems, such as vents, seeps, and whale bones. The thiotrophic symbiosis probably evolved once rather than several times independently. This is supported by the position of the trophosomes at the exact same location in the first segment of the different worms. The remarkable differences of trophosome origins, however, suggest that the last common ancestor harbored symbionts in several tissues. Consequently, in frenulates, the trophosome became restricted to the gut, in Osedax to the somatic mesoderm, and in vestimentiferans and its sister Sclerolinum to the visceral mesoderm. Horizontal transmission not only ensures continuation of symbiosis, it also allows for the uptake of appropriate symbionts, which can be selected in each generation anew. Most remarkably, Osedax, which colonizes whale bones, must have replaced its thiotrophic symbiont with heterotrophic Oceanospirillales nourished by the host.
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Reptiles Richard Shine
Most small children can tell you that 'reptiles' are the snakes, lizards, crocodiles, and turtles (perhaps with the dinosaurs thrown in) -suggesting that it's easy to tell the difference between reptiles and other animals. Unfortunately, evolutionary biologists struggle with the same task, because phylogenetic analysis tells us loud and clear that these different types of what we loosely call 'reptiles' are not particularly closely related to each other (Figure 1 ). On the evolutionary tree, some of them (dinosaurs, crocodiles) are much more closely related to birds than to the other animals that we call reptiles. Other reptiles are the descendants of very ancient lineages; for example, turtles separated from the other reptiles, including the now-dominant Squamata (lizards and snakes), at least 200 million years ago. And another 200-million-year-old lineage has left just a single survivor, a lizardlike creature (the tuatara), on a few islands in New Zealand. So, why do we still talk about 'reptiles', when an analysis based on shared derived traits (cladistics) says that the Reptilia are not a 'natural' (monophyletic) evolutionary group for which a single common ancestor can be defined that excludes all nonreptiles such as birds? The reason is that a comparison based on external morphology (phenetics) would yield the opposite conclusion: for example, crocodiles and tuataras really do look a lot like lizards. For example, they share a distinctive body shape, and are covered in scales. It is this outer resemblance which led to the concept of the Reptilia, and which has kept it alive and kicking even though the creatures known as reptiles are only distantly related to each other. So, the problem with defining the Reptilia actually throws up an interesting biological puzzle: given their divergent ancestries, why do these animals all look so much alike? The answer involves a fundamental feature of reptiles: the way in which they control their body temperature.
Primer
Taking the heat By and large (with more than 8,000 species, there are exceptions to almost every rule), reptiles are ectotherms. That is, they rely upon ambient thermal heterogeneity to regulate their internal temperatures -for example, by basking in sunlight to become warm, and moving to shade to cool down. This tactic is in striking contrast to endotherms, such as birds and mammals, which rely upon metabolic heat production to maintain a high and relatively constant internal temperature. Endotherms are like racing cars -they keep their engines revving at high speed most or all of the time and so can perform at high speed. For example, they not only can move quickly, but they can also maintain that speed because their hearts and lungs can deliver extra oxygen to the muscles that are doing the hard work. And because they generate their own heat, endotherms can function effectively even in cold conditions.
At first sight, this looks like a clear case of an evolutionary advance: the primitive cold-blooded lowperforming reptiles have been replaced by sophisticated highperforming mammals and birds. But that interpretation is wrong: first, ectotherms have not been replaced by endotherms, and when you include fish there are a lot more species of ectothermic vertebrates than endothermic vertebrates. Indeed, some authorities believe that crocodilians evolved from endothermic ancestorssomething we wouldn't expect to happen if endothermy was 'better'. Second, ectotherms are not 'coldblooded' -a desert lizard may run around with a higher body temperature than the rodent who lives in the adjacent burrow. The fundamental difference between endotherms and ectotherms is in the source of the heat used to regulate body temperature: endotherms make their own, whereas ectotherms exploit environmental heat. Because ectotherms do not need to create their own heat, their metabolic rates are about one-tenth of those of a similar-sized endotherm, massively reducing energy needs. They can't fuel sustained muscular activity by aerobic means, but they have a fallback, as anaerobic metabolism usually can keep them going long enough to find the food item or shelter that they require. If endotherms are racing cars, ectotherms are pushbikes, less capable overexpression triggered a G 0 /G 1 -like arrest. Thus, it has been proposed that Plk5 function is related to stress responses.
Are Plks attractive drug targets for cancer treatment? Yes and no -the future will tell. So far, the focus has been on targeting Plk1: human Plk1 is highly expressed in proliferating tissues, often upregulated in tumors, and elevated expression in tumors is associated with poor prognosis. Furthermore, overexpression of Plk1 leads to transformation of cultured cells, likely via the stimulation of a mitotic transcription program involving the transcription factor FOXM1. In addition, it is in principle possible to interfere with Plk1 function not only via the usual route of ATP-competitive inhibitors (which of course raises concerns about specificity), but also by interfering with PBD binding to docking proteins. Several early cell-culture studies had suggested that tumor cells may be more sensitive to Plk1 inhibition than normal cells, but whether a sufficient therapeutic window can be found in a clinically relevant context remains to be determined. Several Plk1 inhibitors are presently in clinical trials and it will be interesting to see how these agents fare for the benefit of patients.
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